Ge Long Hui·2025-07-29 03:08Group 1 - The Hong Kong stock market for innovative drug concepts has strengthened, with WuXi AppTec (药明康德) rising over 9%, Lepu Biopharma (乐普生物) and Green Leaf Pharmaceutical (绿叶制药) rising over 8%, and Xiansheng Pharmaceutical (先声药业) rising over 7% [2] - The innovative drug concept index reached 1722.003, an increase of 40.711 or 2.42%, with a trading volume of 10.42 billion and a total market capitalization of 2.97 trillion [3] Group 2 - WuXi AppTec reported an unaudited interim performance for the six months ending June 30, 2025, with revenue of 20.799 billion yuan, a year-on-year increase of 20.6%; gross profit of 9.112 billion yuan, a year-on-year increase of 36%; and net profit attributable to shareholders of 8.287 billion yuan, a year-on-year increase of 95.5% [4] - The company plans to distribute an interim dividend of 3.5 yuan for every 10 shares [4] - CICC has raised its net profit estimates for 2025/2026 by 8.9% and 9.2% to 12.5 billion yuan and 14.4 billion yuan, respectively [4] - The current A-share price corresponds to a P/E ratio of 21.1x for 2025 and 18.3x for 2026, while the H-share price corresponds to a P/E ratio of 21.5x for 2025 and 18.3x for 2026 [4] - Target prices for A-shares and H-shares have been raised by 45.9% to 115.00 yuan and 59.9% to 126.00 HKD, respectively, reflecting a potential upside of 25.5% [4]